{"title":"Covid-19大流行和疫苗前景:从艾滋病毒/艾滋病中吸取的教训","authors":"G. Ghosh","doi":"10.35248/1948-5964.21.13.209","DOIUrl":null,"url":null,"abstract":"Recent media reported in India those weeks after first vaccine dose during the trial, a Minister got Covid-19. It may have hogged the headline in regard to India’s Covaxin produced by Bharat Biotech. But, the company soon issued a statement defending itself on this count stating, “Covaxin clinical trials are based on a two-dose schedule, given 28 days apart, and the vaccine has been designed to be efficacious when subjects receive both doses.”","PeriodicalId":15020,"journal":{"name":"Journal of Antivirals & Antiretrovirals","volume":"13 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Covid-19 Pandemic and Vaccine Prospect: Lessons Learnt from HIV/AIDS\",\"authors\":\"G. Ghosh\",\"doi\":\"10.35248/1948-5964.21.13.209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent media reported in India those weeks after first vaccine dose during the trial, a Minister got Covid-19. It may have hogged the headline in regard to India’s Covaxin produced by Bharat Biotech. But, the company soon issued a statement defending itself on this count stating, “Covaxin clinical trials are based on a two-dose schedule, given 28 days apart, and the vaccine has been designed to be efficacious when subjects receive both doses.”\",\"PeriodicalId\":15020,\"journal\":{\"name\":\"Journal of Antivirals & Antiretrovirals\",\"volume\":\"13 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Antivirals & Antiretrovirals\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/1948-5964.21.13.209\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antivirals & Antiretrovirals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/1948-5964.21.13.209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Covid-19 Pandemic and Vaccine Prospect: Lessons Learnt from HIV/AIDS
Recent media reported in India those weeks after first vaccine dose during the trial, a Minister got Covid-19. It may have hogged the headline in regard to India’s Covaxin produced by Bharat Biotech. But, the company soon issued a statement defending itself on this count stating, “Covaxin clinical trials are based on a two-dose schedule, given 28 days apart, and the vaccine has been designed to be efficacious when subjects receive both doses.”
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
